AnGes Company Description

AnGes, Inc. engages in the research and development of gene-based medical products.

It develops HGF gene therapy product for the treatment of ischemic diseases; NF-κB Decoy Oligo DNA for chronic discogenic lumber back pain; and DNA vaccines for the treatment of hypertension and cervical intraepithelial neoplasia, as well as intranasal formulation of the COVID-19 vaccine.

The company was formerly known as AnGes MG, Inc. and changed its name to AnGes, Inc. in July 2017. AnGes, Inc. was incorporated in 1999 and is headquartered in Ibaraki, Japan.

AnGes, Inc.

Country	Japan
Founded	1999
Industry	Biotechnology
Sector	Healthcare
Employees	55
CEO	Ei Yamada

Contact Details

Address: Saito Bio-Incubator Ibaraki, 567-0085 Japan
Website	anges.co.jp

Stock Details

Ticker Symbol	4563
Exchange	Tokyo Stock Exchange
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	JPY
ISIN Number	JP3127700007
SIC Code	2834

Key Executives

Name	Position
Ei Yamada	Chief Executive Officer